Incremental effect of topical and oral moxifloxacin administration with surgical intracameral prophylaxis

[1]  S. Arshinoff,et al.  Aqueous level abatement profiles of intracameral antibiotics: A comparative mathematical model of moxifloxacin, cefuroxime, and vancomycin with determination of relative efficacies. , 2019, Journal of cataract and refractive surgery.

[2]  D. Chang,et al.  Endophthalmitis reduction with intracameral moxifloxacin in eyes with and without surgical complications: Results from two-million consecutive cataract surgeries. , 2019, Journal of cataract and refractive surgery.

[3]  F. Lum,et al.  Endophthalmitis after Cataract Surgery in the United States: A Report from the Intelligent Research in Sight Registry, 2013-2017. , 2019, Ophthalmology.

[4]  A. Abdel-Meguid,et al.  Comparative Study Between Topical Gatifloxacin 0.5% and Moxifloxacin 0.5% as a Prophylactic Measure Before Intraocular Surgery. , 2019, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[5]  T. Greene,et al.  Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis , 2018, British Journal of Ophthalmology.

[6]  L. A. Melo,et al.  Aqueous humor concentrations of topical fluoroquinolones alone or in combination with a steroid. , 2017, Arquivos brasileiros de oftalmologia.

[7]  D. Chang,et al.  Endophthalmitis Reduction with Intracameral Moxifloxacin Prophylaxis: Analysis of 600 000 Surgeries. , 2017, Ophthalmology.

[8]  Sean Mathews,et al.  Endophthalmitis prophylaxis by intracameral antibiotics: In vitro model comparing vancomycin, cefuroxime, and moxifloxacin. , 2017, Journal of cataract and refractive surgery.

[9]  K. Kenyon,et al.  Aqueous Humor Penetration and Biological Activity of Moxifloxacin 0.5% Ophthalmic Solution Alone or with Dexamethasone 0.1. , 2017, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[10]  P. Asbell,et al.  Antibiotic susceptibility of bacterial pathogens isolated from the aqueous and vitreous humor in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. , 2016, Journal of cataract and refractive surgery.

[11]  S. Arshinoff,et al.  Dose and administration of intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis , 2016, Journal of cataract and refractive surgery.

[12]  F. Bucci,et al.  Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery , 2016, Clinical ophthalmology.

[13]  M. Jabbarvand,et al.  Endophthalmitis Occurring after Cataract Surgery: Outcomes of More Than 480 000 Cataract Surgeries, Epidemiologic Features, and Risk Factors. , 2016, Ophthalmology.

[14]  D. Chang,et al.  Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery: Results of the 2014 ASCRS member survey , 2015, Journal of cataract and refractive surgery.

[15]  Rajesh R Nayak,et al.  Aqueous penetration of orally and topically administered moxifloxacin , 2015, British Journal of Ophthalmology.

[16]  J. Hjortdal,et al.  Antibiotic prevention of postcataract endophthalmitis: a systematic review and meta‐analysis , 2015, Acta ophthalmologica.

[17]  E. Weis,et al.  Antibiotic choice for the prophylaxis of post-cataract extraction endophthalmitis. , 2014, Ophthalmology.

[18]  T. Mandal,et al.  Comparative evaluation of aqueous and plasma concentration of topical moxifloxacin alone and with flurbiprofen in patients of cataract surgery , 2013, Indian journal of pharmacology.

[19]  L. Drolsum,et al.  Endophthalmitis following cataract surgery: the role of prophylactic postoperative chloramphenicol eye drops , 2013, Acta ophthalmologica.

[20]  U. Stenevi,et al.  Six‐year incidence of endophthalmitis after cataract surgery: Swedish national study , 2013, Journal of cataract and refractive surgery.

[21]  L. Herrinton,et al.  Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department , 2013, Journal of cataract and refractive surgery.

[22]  C. Cook,et al.  Endophthalmitis prophylaxis with intracameral cefuroxime in South Africa. , 2012, Journal of cataract and refractive surgery.

[23]  P. Robert,et al.  Intracameral cefuroxime injection at the end of cataract surgery to reduce the incidence of endophthalmitis: French study , 2012, Journal of cataract and refractive surgery.

[24]  T. Nakazawa,et al.  Comparison of Corneal and Aqueous Humor Penetration of Moxifloxacin, Gatifloxacin and Levofloxacin during Keratoplasty , 2012, Advances in Therapy.

[25]  S. Arshinoff,et al.  Incidence of postoperative endophthalmitis after immediate sequential bilateral cataract surgery , 2011, Journal of cataract and refractive surgery.

[26]  E. Donnenfeld,et al.  Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application , 2011, Journal of cataract and refractive surgery.

[27]  M. Babaoğlu,et al.  Aqueous humour penetration of moxifloxocin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery , 2010, British Journal of Ophthalmology.

[28]  W. Stark,et al.  Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients , 2010, Journal of cataract and refractive surgery.

[29]  G. Rodríguez-Caravaca,et al.  Effectiveness of intracameral cefuroxime in preventing endophthalmitis after cataract surgery: Ten‐year comparative study , 2010, Journal of cataract and refractive surgery.

[30]  J. Blondeau.  New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. , 2009, Veterinary dermatology.

[31]  C. L. Moser,et al.  Prophylactic intracameral cefazolin after cataract surgery: Endophthalmitis risk reduction and safety results in a 6‐year study , 2009, Journal of cataract and refractive surgery.

[32]  A. Vasavada,et al.  Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: Prospective randomized triple‐masked trial: Part 1: Aqueous concentration of moxifloxacin , 2008, Journal of cataract and refractive surgery.

[33]  Terry Kim,et al.  Ocular Penetration and Pharmacokinetics of Topical Gatifloxacin 0.3% and Moxifloxacin 0.5% Ophthalmic Solutions After Keratoplasty , 2008, Cornea.

[34]  S. Masket,et al.  Prophylaxis of postoperative endophthalmitis after cataract surgery: Results of the 2007 ASCRS member survey , 2007, Journal of cataract and refractive surgery.

[35]  K. Choy,et al.  Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. , 2007, American journal of ophthalmology.

[36]  S. Bode-Böger,et al.  Concentration of moxifloxacin in serum and human aqueous humor following a single 400 mg oral dose , 2007, Journal of cataract and refractive surgery.

[37]  L. Ong-Tone.  Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery , 2007, Journal of cataract and refractive surgery.

[38]  K. Ramasamy,et al.  Vitreous and aqueous penetration of orally administered moxifloxacin in humans , 2006, Eye.

[39]  A. Venkatraman,et al.  The effect of moxifloxacin on the normal human cornea , 2006, Current medical research and opinion.

[40]  J. McCulley,et al.  Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. , 2006, Ophthalmology.

[41]  G. Gettinby,et al.  ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: Preliminary report of principal results from a European multicenter study , 2006, Journal of cataract and refractive surgery.

[42]  Juan Fernández,et al.  Intracameral cefazolin as prophylaxis against endophthalmitis in cataract surgery , 2006, Journal of cataract and refractive surgery.

[43]  J. Dick,et al.  Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. , 2005, Ophthalmology.

[44]  S. Masket,et al.  Absorption of Topical Moxifloxacin Ophthalmic Solution Into Human Aqueous Humor , 2005, Cornea.

[45]  D. Dahlin,et al.  Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. , 2005, Survey of ophthalmology.

[46]  E. Romanowski,et al.  Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. , 2005, American journal of ophthalmology.

[47]  M. Abelson,et al.  Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. , 2005, Archives of ophthalmology.

[48]  A. Antoniadou,et al.  Penetration of moxifloxacin into the human aqueous humour after oral administration , 2005, British Journal of Ophthalmology.

[49]  U. Stenevi,et al.  Endophthalmitis following cataract surgery in Sweden: national prospective survey 1999-2001. , 2005, Acta ophthalmologica Scandinavica.

[50]  C. Nedrud,et al.  Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. , 2004, Ophthalmology.

[51]  Matthew A. Thomas,et al.  Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. , 2005, Archives of ophthalmology.

[52]  F. Mah.  Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections , 2004, Current opinion in ophthalmology.

[53]  D. Hwang.  Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. , 2004, Survey of ophthalmology.

[54]  W. Mieler,et al.  Vitreous and aqueous penetration of orally administered gatifloxacin in humans. , 2004 .

[55]  E. Romanowski,et al.  Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. , 2003, American journal of ophthalmology.

[56]  C. Zetterström,et al.  Prophylactic intracameral cefuroxime: Evaluation of safety and kinetics in cataract surgery , 2002, Journal of cataract and refractive surgery.

[57]  E. Romanowski,et al.  Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. , 2002, American journal of ophthalmology.

[58]  A. Arias‐Puente,et al.  Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin , 2001, Journal of cataract and refractive surgery.

[59]  H. Stass,et al.  Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. , 1999, The Journal of antimicrobial chemotherapy.

[60]  A. Bauernfeind.  Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. , 1997, The Journal of antimicrobial chemotherapy.

[61]  C. Stratton,et al.  Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies , 1987, Antimicrobial Agents and Chemotherapy.